Never miss a story

Get subscribed to our newsletter


×
FILE - A Congolese health worker administers Ebola vaccine to a child at the Himbi Health Centre in Goma, Democratic Republic of Congo, July 17, 2019. VOA

The resignation of Congo’s health minister in the midst of the country’s worst Ebola outbreak could clear the way for a second experimental vaccine to be deployed. But the new shot would likely take months to win the trust of frightened locals and show results, health officials say.

Oly Ilunga, who opposed using the vaccine developed by U.S. pharmaceutical giant Johnson & Johnson, resigned as minister Monday after being bumped off the Ebola response team. The World Health Organization recommended the two-dose shot to complement a vaccine by U.S. drugmaker Merck, which has proved highly protective but is in relatively short supply.


Firewall against virus

Proponents, including medical charity Medecins Sans Frontieres (Doctors Without Borders) and the Wellcome Trust, said the new vaccine could be deployed to areas not yet affected by Ebola to create a firewall against the virus, which the WHO declared an international health emergency last week.

But Ilunga said the J&J vaccine had not been proved effective and could confuse people in eastern Democratic Republic of Congo, where wild rumors are hampering the response. “Congolese have the right to have the gold standard, the best vaccine,” he told Reuters Thursday, in his first public comments since resigning. “They don’t need to be the subject of experimentation.”

“You can’t have a group of promoters, producers of the vaccine (and) university researchers wanting to introduce the vaccine without contacting the health authorities,” he said, without elaborating further.

Paul Stoffels, J&J’s chief scientific officer, denied there were any efforts to secretly introduce the vaccine and said the company had been in full communication with Congolese authorities.


World Health Organization (WHO) director-general Tedros Adhanom Ghebreyesus, right, listens to a delegate at the end of a meeting organized by the United Nations on the Ebola in Democratic Republic of Congo, July 15, 2019, in Geneva. VOA

Skepticism

But skepticism about new medicines can resonate strongly on a continent where some pharmaceutical trials have faced accusations in the past of failing to obtain informed consent and providing subpar care to participants.

For example, some U.S. government-funded trials of HIV drugs in the 1990s were accused of double standards for giving placebos to women in Africa when effective therapies existed, a practice that is not generally allowed in the United States and other Western nations on ethical grounds. Researchers defended the use of placebos as scientifically necessary.

Jean-Jacques Muyembe, an epidemiologist and Ebola expert named to lead Congo’s response team, dismissed Ilunga’s concerns and said authorities would revisit whether to deploy a second vaccine.

However, he downplayed the importance of the decision. “I don’t think that a vaccine is what’s holding back the response,” he told Reuters, noting that previous Ebola outbreaks had been contained quickly without a vaccine. “We could use or not use. It won’t change the evolution of the epidemic,” he said.

‘Not ethical’

The nearly yearlong outbreak has infected more than 2,500 people and killed more than 1,700, numbers topped only by a 2014-16 outbreak in West Africa that killed more than 11,300. This month, a case was detected in Goma, a city of 2 million on the border with Rwanda, heightening fears about the spread of the hemorrhagic fever.

Efforts to contain it have been undermined by mistrust of health workers and violence by armed militias. Treatment centers have been attacked. Local campaigners say people are scared and confused about the various medicines being used. In addition to the vaccine, four experimental treatments are being given to Ebola patients. All are still unlicensed, which means they can only be used in clinical trials overseen by Congo’s health ministry.

“We should not introduce a second vaccine when we don’t yet have scientifically proven conclusions from the one currently being tested,” said Matina Mwanack, the administrator of an advocacy group in the eastern Congo city of Butembo called Families United Against Ebola. “(We) have suffered a lot from the lack of needed information about the vaccines and treatments being tested.”

Omar Kavota, who heads a group of religious and political leaders in eastern Congo, said “introducing a second vaccine would amplify rumors,” including over why some patients got one while others received the second. Muyembe said communicators had been appointed to make the process more transparent.


A worker from the World Health Organization decontaminates the doorway of a house on a plot where two cases of Ebola were found, in the village of Mabalako, in eastern Congo, June 17, 2019. Health officials in eastern Congo began offering vaccines. VOA

Stockpiles

Proponents of a second vaccine argue it can only be tested in a live outbreak, since it would be unethical to deliberately infect trial volunteers. They propose deploying it where the disease has not yet spread, while the Merck vaccine continues to be used to protect contacts of suspected cases.

“Both vaccines should work hand in hand,” said Peter Piot, director of the London School of Hygiene and Tropical Medicine and one of the scientists who first discovered the Ebola virus. Since the West African outbreak, J&J has tested its vaccine on more than 6,000 volunteers in a dozen trials, confirming its safety and ability to generate an immune response.

It requires two injections 56 days apart — another obstacle cited by Ilunga — in an area where fighting causes frequent displacement, but should last longer. “The goal is to give a long-term safe profile for people who may never be exposed to Ebola,” said J&J’s Stoffels, adding that 1.5 million doses were available.

Josie Golding, head of epidemics at the Wellcome Trust, said “we could run out of Merck vaccines” if the outbreak extends into a second year. Health authorities have already begun using smaller doses to ration supplies.

ALSO READ: WHO: Ebola Epidemic in Congo a Public Health Emergency of International Concern

Congo’s health ministry disputes there is a shortage of the Merck vaccine. The company said it expects to have about 900,000 doses available over the next six to 18 months, in addition to the 195,000 doses it has already donated.

The ministry has also considered potential vaccines developed by China’s CanSino Biologics and the Russian research institutes Rospotrebnadzor and Gamaleya, but those discussions are less advanced. (VOA)


Popular

Unsplash

The researchers exposed saliva samples from Covid-19 patients to the ACE2 gum and found that levels of viral RNA fell so dramatically to be almost undetectable.

A chewing gum laced with a plant-grown protein serves as a "trap" for the SARS-CoV-2 virus, reducing viral load in saliva and potentially tamping down transmission, finds a new study.

The researchers exposed saliva samples from Covid-19 patients to the ACE2 gum and found that levels of viral RNA fell so dramatically to be almost undetectable, indicates the study published in the journal Molecular Therapy.

Follow NewsGram on Instagram to keep yourself updated.

"SARS-CoV-2 replicates in the salivary glands, and we know that when someone d sneezes, coughs, or speaks some of that virus can be expelled and reach others," said researcher Henry Daniell from the University of Pennsylvania in the US.

"This gum offers an opportunity to neutralise the virus in the saliva, giving us a simple way to possibly cut down on a source of disease transmission," Daniell added.

To test the chewing gum, the team grew angiotensin-converting enzyme 2 (ACE2) in plants, paired with another compound that enables the protein to cross mucosal barriers and facilitates binding, and incorporated the resulting plant material into cinnamon-flavoured gum tablets.

Keep Reading Show less

HUH Token

After the release of HUH Token’s White Paper and the buzz around the soon-to-be launching cryptocurrency, it’s no wonder that the crypto world is wondering whether or not Shiba Inu’s year of meme coin supremacy is coming to an end.

Shiba Inu rose to crypto fame in the august of 2020 and just a little over a year from that point, where Shiba Inu knocked Dogecoin off top dog spot… it appears that HUH Token could be set to take the cryptocurrency world by storm on its launch: Monday December 6th. And with it the possible end of Shiba Inu’s reign as the supreme meme coin.

Keep Reading Show less

HUH Token

Investing in the cryptocurrency business is one of the most intelligent choices one can make in the modern-day. In 2021, the sector exhibited its promise, with cryptocurrencies like Ethereum (ETH), Bitcoin (BTC) and Shiba Inu (SHIB) seeing optimistic growth and creating numerous billionaire investors. The market is still in its infancy, and there is an impossible number of exciting cryptocurrencies available for investment. HUH Token, for instance, is one of these, and it is releasing today!

Comprehending a cryptocurrency’s most recent release helps to compare it to previous accomplishments. HUH Token (HUH), Cardano (ADA) and Solana (SOL) are three cryptocurrencies that every crypto trader should be familiar with. These are coins with high usefulness and a robust growth plan. Cardano and Solana are two growing blockchain technologies in the crypto world.

Keep reading... Show less